

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Ertugliflozin (< 5%) / Sitagliptin Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Innishannon
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Skin irritation, Category 2	H315: Causes skin irritation.
Serious eye damage, Category 1	H318: Causes serious eye damage.
Long-term (chronic) aquatic hazard, Cat- egory 3	H412: Harmful to aquatic life with long lasting ef- fects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H315 Causes skin irritation.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

H318 Causes serious eye damage.
H412 Harmful to aquatic life with long lasting effects.

Precautionary statements	:	Prevention: P264 Wash skin thoroughly after handling. P273 Avoid release to the environment. P280 Wear protective gloves/ eye protection/ face protection.
		Response: P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
		P332 + P313 If skin irritation occurs: Get medical advice/ attention.
		P362 + P364 Take off contaminated clothing and wash it before reuse.

Hazardous components which must be listed on the label:

Ertugliflozin

Additional Labelling

EUH208 Contains Propyl 3,4,5-trihydroxybenzoate. May produce an allergic reaction.

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Sitagliptin Phosphate	654671-77-9	Eye Irrit. 2; H319	>= 30 - < 50

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1 Revision Date: 11.08.2025 SDS Number: 2403219-00018 Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

Ertugliflozin	1210344-83-4	Acute Tox. 4; H302 Skin Corr. 1B; H314 Eye Dam. 1; H318 STOT RE 2; H373 (Kidney, Stomach, Prostate)	>= 3 - < 5
Propyl 3,4,5-trihydroxybenzoate	121-79-9 204-498-2 607-198-00-3	Acute Tox. 4; H302 Eye Dam. 1; H318 Skin Sens. 1; H317 Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1 Acute toxicity esti- mate Acute oral toxicity: 1,700 mg/kg	>= 0.25 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May produce an allergic reaction.

Causes skin irritation.
Causes serious eye damage.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Oxides of phosphorus

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Do not get in eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1	Revision Date: 11.08.2025	SDS Number: 2403219-00018	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Hygiene measures	<p>Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.</p> <p>If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</p>
------------------	--

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	: Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.
Advice on common storage	: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s)	: No data available
-----------------	---------------------

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

dusts non-specific	4 mg/m ³ Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust) Basis: IE OEL
	10 mg/m ³ Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust) Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Sitagliptin Phosphate	654671-77-9	TWA	0.6 mg/m ³ (OEB 2)	Internal
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m ³	IE OEL
Ertugliflozin	1210344-83-4	TWA	10 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1 Revision Date: 11.08.2025 SDS Number: 2403219-00018 Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

Magnesium stearate	557-04-0	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
--------------------	----------	--------------------	----------	--------

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Propyl 3,4,5-trihydroxybenzoate	Workers	Inhalation	Long-term systemic effects	6.66 mg/m3
	Workers	Skin contact	Long-term systemic effects	1.89 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	1.17 mg/m3
	Consumers	Skin contact	Long-term systemic effects	0.675 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.675 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propyl 3,4,5-trihydroxybenzoate	Fresh water	0.37 µg/l
	Freshwater - intermittent	3.7 µg/l
	Marine water	0.037 µg/l
	Marine water - intermittent	0.37 µg/l
	Sewage treatment plant	6.36 mg/l
	Fresh water sediment	0.0045 mg/kg dry weight (d.w.)
	Marine sediment	0.00045 mg/kg dry weight (d.w.)
	Soil	0.000688 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1	Revision Date: 11.08.2025	SDS Number: 2403219-00018	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Remarks	:	Consider double gloving.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity		
Viscosity, kinematic	:	Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1 Revision Date: 11.08.2025 SDS Number: 2403219-00018 Date of last issue: 14.04.2025 Date of first issue: 01.02.2018

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics
Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025
5.1 11.08.2025 2403219-00018 Date of first issue: 01.02.2018

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Sitagliptin Phosphate:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg
LD50 (Mouse): 3,000 mg/kg

Ertugliflozin:

Acute oral toxicity : LD50 (Rat): 500 mg/kg
Acute inhalation toxicity : Remarks: No data available
Acute dermal toxicity : Remarks: No data available

Propyl 3,4,5-trihydroxybenzoate

Acute oral toxicity : LD50 (Mouse): 1,700 mg/kg
Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Skin corrosion/irritation

Causes skin irritation

Components:

Sitagliptin Phosphate:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Ertugliflozin:

Result : Corrosive

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

Propyl 3,4,5-trihydroxybenzoate:

Species : reconstructed human epidermis (RhE)
Method : OECD Test Guideline 439

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Sitagliptin Phosphate:

Species : Rabbit
Method : Draize Test
Result : Irritating to eyes.

Ertugliflozin:

Result : Severe irritation

Propyl 3,4,5-trihydroxybenzoate:

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Sitagliptin Phosphate:

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Ertugliflozin:

Test Type : Local lymph node assay (LLNA)
Result : Not a skin sensitizer.

Propyl 3,4,5-trihydroxybenzoate:

Test Type : Local lymph node assay (LLNA)
Exposure routes : Skin contact
Species : Mouse

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1	Revision Date: 11.08.2025	SDS Number: 2403219-00018	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Result : positive

Assessment : Probability or evidence of skin sensitisation in humans

Germ cell mutagenicity

Not classified based on available information.

Components:

Sitagliptin Phosphate:

Genotoxicity in vitro	: Test Type: Ames test Result: negative
	Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells Result: negative
	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro) Test system: rat hepatocytes Result: negative
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative

Ertugliflozin:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Rat Result: negative

Propyl 3,4,5-trihydroxybenzoate:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Result: positive
	Test Type: Chromosome aberration test in vitro Result: positive
	Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1	Revision Date: 11.08.2025	SDS Number: 2403219-00018	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Result: negative

Test Type: In vitro sister chromatid exchange assay in mammalian cells

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Sitagliptin Phosphate:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : oral (drinking water)
Exposure time : 2 Years
Result : positive
Target Organs : Liver
Remarks : Significant toxicity observed in testing

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

Ertugliflozin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

Propyl 3,4,5-trihydroxybenzoate:

Species : Rat
Application Route : Ingestion
Exposure time : 103 weeks

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1	Revision Date: 11.08.2025	SDS Number: 2403219-00018	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Sitagliptin Phosphate:

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL Parent: 1,000 mg/kg body weight
Result: Animal testing did not show any effects on fertility.
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Teratogenicity: LOAEL: 250 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects
- Test Type: Embryo-foetal development
Species: Rabbit
Teratogenicity: NOAEL: 125 mg/kg body weight
Result: No teratogenic effects

Ertugliflozin:

- Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL: 250 mg/kg body weight
Remarks: Maternal toxicity observed.
No significant adverse effects were reported
- Test Type: Fertility/early embryonic development
Species: Rabbit
Application Route: Oral
Fertility: NOAEL: 200 mg/kg body weight
Remarks: No significant adverse effects were reported
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 50 mg/kg body weight
Remarks: Adverse developmental effects were observed
- Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 250 mg/kg body weight
Remarks: No significant adverse effects were reported

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

Propyl 3,4,5-trihydroxybenzoate:

- Effects on fertility : Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative
- Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

Ertugliflozin:

- Exposure routes : Oral
Target Organs : Kidney, Stomach, Prostate
Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Sitagliptin Phosphate:

- Species : Mouse
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : > 2 yr
Target Organs : Kidney
- Species : Rat
NOAEL : 500 mg/kg
LOAEL : 1,000 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Target Organs : Liver, Kidney, Heart, Teeth
- Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Loss of balance
Remarks : The mechanism or mode of action may not be relevant in hu-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025
5.1 11.08.2025 2403219-00018 Date of first issue: 01.02.2018

mans.

Species	:	Dog
NOAEL	:	2 mg/kg
LOAEL	:	10 mg/kg
Application Route	:	Oral
Exposure time	:	27 Weeks
Target Organs	:	Skeletal muscle, Central nervous system
Symptoms	:	Loss of balance
Remarks	:	The mechanism or mode of action may not be relevant in humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks
Remarks : No significant adverse effects were reported

Ertugliflozin:

Species : Rat
LOAEL : 500 mg/kg
Application Route : Oral
Exposure time : 30 d

Species	:	Rat
LOAEL	:	250 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Kidney

Species : Rat
LOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 180 d
Target Organs : Kidney, Bone, Stomach

Species : Rat
LOAEL : 25 mg/kg
Exposure time : 90 d
Target Organs : Kidney, Gastrointestinal tract, Prostate

Species : Dog
NOAEL : 150 mg/kg
Application Route : Oral
Exposure time : 270 d
Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 90 d
Remarks : No significant adverse effects were reported

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1 Revision Date: 11.08.2025 SDS Number: 2403219-00018 Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

Species	:	Mouse
NOAEL	:	100 mg/kg
Application Route	:	Oral
Exposure time	:	28 d
Target Organs	:	Bone
Remarks	:	No significant adverse effects were reported

Propyl 3,4,5-trihydroxybenzoate:

Species	:	Rat
NOAEL	:	135 mg/kg
Application Route	:	Ingestion
Exposure time	:	13 Weeks

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
------------	---	---

Experience with human exposure

Components:

Sitagliptin Phosphate:

Inhalation	:	Symptoms: upper respiratory tract infection, pharyngitis, Headache
Ingestion	:	Symptoms: upper respiratory tract infection, nasopharyngitis, Headache, Nausea, Abdominal pain, Diarrhoea

Ertugliflozin:

Ingestion	:	Symptoms: The most common side effects are:, Headache, constipation, Diarrhoea, Nausea, urinary tract infection, muscle pain, upper respiratory tract infection
-----------	---	---

SECTION 12: Ecological information

12.1 Toxicity

Components:

Sitagliptin Phosphate:

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l
------------------	---	---

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 60 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 39 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 150 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC : 150 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Toxicity to fish (Chronic toxicity) : NOEC: 9.2 mg/l
Exposure time: 33 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 9.8 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Ertugliflozin:

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): 77 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 50 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC : 1,000 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025
5.1 11.08.2025 2403219-00018 Date of first issue: 01.02.2018

Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 1 mg/l
Exposure time: 32 d
Species: *Pimephales promelas* (fathead minnow)
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 2.14 mg/l
Exposure time: 21 d
Species: *Daphnia magna* (Water flea)
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

Propyl 3,4,5-trihydroxybenzoate:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 19.6 mg/l
Exposure time: 48 h
Test substance: Neutralised product
Method: OECD Test Guideline 202
Remarks: The test was conducted according to guideline

Toxicity to algae/aquatic plants : ErC50 (Pseudokirchneriella subcapitata (green algae)): 0.22 mg/l
Exposure time: 72 h
Test substance: Neutralised product
Method: OECD Test Guideline 201
Remarks: The test was conducted according to guideline

EC10 (Pseudokirchneriella subcapitata (green algae)): 0.096 mg/l
Exposure time: 72 h
Test substance: Neutralised product
Method: OECD Test Guideline 201
Remarks: The test was conducted according to guideline

M-Factor (Acute aquatic toxicity) : 1

Toxicity to microorganisms : EC50 (activated sludge): 636 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

M-Factor (Chronic aquatic toxicity) : 1

12.2 Persistence and degradability

Components:

Sitagliptin Phosphate:

Biodegradability : Result: not rapidly degradable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version 5.1	Revision Date: 11.08.2025	SDS Number: 2403219-00018	Date of last issue: 14.04.2025 Date of first issue: 01.02.2018
----------------	------------------------------	------------------------------	---

Biodegradation: 39.7 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Stability in water : pH: 7
Hydrolysis: 50 %(401 d)
Method: OECD Test Guideline 111

Ertugliflozin:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 40.8 %
Exposure time: 28 d

Propyl 3,4,5-trihydroxybenzoate:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 49.4 %
Exposure time: 28 d
Method: OECD Test Guideline 301F

12.3 Bioaccumulative potential

Components:

Sitagliptin Phosphate:

Partition coefficient: n-octanol/water : log Pow: -0.03

Ertugliflozin:

Partition coefficient: n-octanol/water : log Pow: 2.47

Propyl 3,4,5-trihydroxybenzoate:

Partition coefficient: n-octanol/water : log Pow: 1.8
Remarks: Calculation

12.4 Mobility in soil

Components:

Sitagliptin Phosphate:

Distribution among environmental compartments : log Koc: 4.37

Ertugliflozin:

Distribution among environmental compartments : log Koc: 2.88

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product

: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging

: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN

: Not regulated as a dangerous good

ADR

: Not regulated as a dangerous good

RID

: Not regulated as a dangerous good

IMDG

: Not regulated as a dangerous good

IATA

: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN

: Not regulated as a dangerous good

ADR

: Not regulated as a dangerous good

RID

: Not regulated as a dangerous good

IMDG

: Not regulated as a dangerous good

IATA

: Not regulated as a dangerous good

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)

: Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

: Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version Revision Date: SDS Number: Date of last issue: 14.04.2025
5.1 11.08.2025 2403219-00018 Date of first issue: 01.02.2018

Regulation (EU) No 2024/590 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.		Not applicable

The components of this product are reported in the following inventories:

AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H314 : Causes severe skin burns and eye damage.
H317 : May cause an allergic skin reaction.
H318 : Causes serious eye damage.
H319 : Causes serious eye irritation.
H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.
H400 : Very toxic to aquatic life.
H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Acute	: Short-term (acute) aquatic hazard
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Eye Dam.	: Serious eye damage
Eye Irrit.	: Eye irritation
Skin Corr.	: Skin corrosion
Skin Sens.	: Skin sensitisation
STOT RE	: Specific target organ toxicity - repeated exposure
IE OEL	: Ireland. List of Chemical Agents and Carcinogens with Occup-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

pational Exposure Limit Values - Code of Practice, Schedule 1
and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Skin Irrit. 2	H315
Eye Dam. 1	H318
Aquatic Chronic 3	H412

Classification procedure:

Calculation method
Calculation method
Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Ertugliflozin (< 5%) / Sitagliptin Formulation

Version
5.1

Revision Date:
11.08.2025

SDS Number:
2403219-00018

Date of last issue: 14.04.2025
Date of first issue: 01.02.2018

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN